Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors
Source abstract
Abstract
Solid tumors develop as 3D tissue constructs. As tumors grow larger, spatial gradients of nutrients and oxygen and inadequate diffusive supply to cells distant from vasculature develops. Hypoxia initiates signaling and transcriptional alterations to promote survival of cancer cells and generation of cancer stem cells (CSCs) that have self‐renewal and tumor‐initiation capabilities. Both hypoxia and CSCs are associated with resistance to therapies and tumor relapse. This study demonstrates that 3D cancer cell models, known as tumor spheroids, generated with a polymeric aqueous two‐phase system (ATPS) technology capture these important biological processes. Similar to solid tumors, spheroids of triple negative breast cancer cells deposit major extracellular matrix proteins. The molecular analysis establishes presence of hypoxic cells in the core region and expression of CSC gene and protein markers including CD24, CD133, and Nanog. Importantly, these spheroids resist treatment with chemotherapy drugs. A combination treatment approach using a hypoxia‐activated prodrug, TH‐302, and a chemotherapy drug, doxorubicin, successfully targets drug resistant spheroids. This study demonstrates that ATPS spheroids recapitulate important biological and functional properties of solid tumors and provide a unique model for studies in cancer research.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer, Hypoxia, and Metabolism · Metabolomics and Mass Spectrometry Studies · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering The University of Akron Akron OH 44325 USA
Department of Radiology Microbiology and Immunology, and Biomedical Engineering University of Michigan Ann Arbor MI 48109 USA
References (95)
Show source-provided references
1. 10.1016/j.biotechadv.2014.07.00910.1016/j.biotechadv.2014.07.009 ↗
2. 10.1038/nrc109810.1038/nrc1098 ↗
3. 10.1038/nature0978110.1038/nature09781 ↗
4. 10.1093/jnci/djm13510.1093/jnci/djm135 ↗
5. 10.1007/BF0068963310.1007/BF00689633 ↗
6. 10.1073/pnas.142101811210.1073/pnas.1421018112 ↗
7. 10.1002/icl3.103910.1002/icl3.1039 ↗
8. 10.1016/j.tips.2012.01.00510.1016/j.tips.2012.01.005 ↗
9. 10.1016/j.cell.2012.01.02110.1016/j.cell.2012.01.021 ↗
10. 10.1016/j.drup.2011.03.00110.1016/j.drup.2011.03.001 ↗
11. 10.1038/nrm223610.1038/nrm2236 ↗
12. 10.1089/ten.tea.2012.033310.1089/ten.tea.2012.0333 ↗
13. 10.1002/adhm.20150010710.1002/adhm.201500107 ↗
14. 10.1177/153537021664377210.1177/1535370216643772 ↗
15. 10.1002/adhm.20150044110.1002/adhm.201500441 ↗
16. 10.1007/s40265-013-0091-610.1007/s40265-013-0091-6 ↗
17. 10.1021/la500930x10.1021/la500930x ↗
18. 10.1021/acsami.5b0575710.1021/acsami.5b05757 ↗
19. 10.1002/adma.20090427110.1002/adma.200904271 ↗
20. 10.1002/biot.20130022710.1002/biot.201300227 ↗
21. 10.1039/C5IB00121H10.1039/C5IB00121H ↗
22. 10.1155/2013/42060110.1155/2013/420601 ↗
23. 10.1007/s12195-014-0349-410.1007/s12195-014-0349-4 ↗
24. 10.1016/j.diii.2012.01.00610.1016/j.diii.2012.01.006 ↗
25. 10.1016/j.yexcr.2013.02.00610.1016/j.yexcr.2013.02.006 ↗
26. 10.1016/j.breast.2013.07.01210.1016/j.breast.2013.07.012 ↗
27. 10.1080/0955300031000161024010.1080/09553000310001610240 ↗
28. 10.1038/nrc306410.1038/nrc3064 ↗
29. 10.1038/nrc189310.1038/nrc1893 ↗
30. 10.1016/S0305-7372(03)00003-310.1016/S0305-7372(03)00003-3 ↗
31. 10.1016/j.ctrv.2012.08.00410.1016/j.ctrv.2012.08.004 ↗
32. 10.1158/1535-7163.MCT-14-047610.1158/1535-7163.MCT-14-0476 ↗
33. 10.1038/nrc136710.1038/nrc1367 ↗
34. 10.1186/1471-2407-14-40010.1186/1471-2407-14-400 ↗
35. 10.1038/sj.bjc.660484410.1038/sj.bjc.6604844 ↗
36. 10.1371/journal.pone.002508010.1371/journal.pone.0025080 ↗
37. 10.4161/cc.2112710.4161/cc.21127 ↗
38. 10.1128/MCB.23.1.359-369.200310.1128/MCB.23.1.359-369.2003 ↗
39. 10.1158/1535-7163.MCT-08-019810.1158/1535-7163.MCT-08-0198 ↗
40. 10.1038/sj.onc.120643410.1038/sj.onc.1206434 ↗
41. 10.1128/MCB.24.7.2875-2889.200410.1128/MCB.24.7.2875-2889.2004 ↗
42. 10.1007/s12032-016-0755-710.1007/s12032-016-0755-7 ↗
43. 10.1038/nrc359910.1038/nrc3599 ↗
44. 10.1158/1535-7163.MCT-11-063410.1158/1535-7163.MCT-11-0634 ↗
45. 10.1080/15384047.2014.100300510.1080/15384047.2014.1003005 ↗
46. 10.1186/s12885-015-1387-610.1186/s12885-015-1387-6 ↗
47. 10.1124/pr.58.3.1010.1124/pr.58.3.10 ↗
48. Tyagi A. · Oncol. Rep. · 2004 · 11 · 493
49. Sun J. D. · Am. J. Cancer Res. · 2015 · 5 · 2139
50. 10.1158/1078-0432.CCR-15-001810.1158/1078-0432.CCR-15-0018 ↗
51. 10.1200/JCO.2013.54.366010.1200/JCO.2013.54.3660 ↗
52. Arola O. J. · Cancer Res. · 2000 · 60 · 1789
53. 10.1007/s00005-009-0051-810.1007/s00005-009-0051-8 ↗
54. 10.1007/BF0069598710.1007/BF00695987 ↗
55. 10.1007/BF0068515410.1007/BF00685154 ↗
56. 10.1038/bjc.1986.19210.1038/bjc.1986.192 ↗
57. 10.1016/j.cell.2007.04.01910.1016/j.cell.2007.04.019 ↗
58. 10.1038/sj.bjc.660555110.1038/sj.bjc.6605551 ↗
59. 10.1038/bcj.2014.8210.1038/bcj.2014.82 ↗
60. 10.1016/j.canlet.2016.03.01410.1016/j.canlet.2016.03.014 ↗
61. 10.1038/srep1807410.1038/srep18074 ↗
62. 10.1023/A:102293931810210.1023/A:1022939318102 ↗
63. 10.2217/nnm.12.2210.2217/nnm.12.22 ↗
64. 10.1038/ncb271710.1038/ncb2717 ↗
65. 10.1073/pnas.053029110010.1073/pnas.0530291100 ↗
66. 10.1172/JCI4474510.1172/JCI44745 ↗
67. 10.1007/s10549-011-1865-810.1007/s10549-011-1865-8 ↗
68. 10.1186/1756-9966-31-5910.1186/1756-9966-31-59 ↗
69. 10.1016/j.canlet.2014.06.02210.1016/j.canlet.2014.06.022 ↗
70. 10.1038/nrd425310.1038/nrd4253 ↗
71. Huebschman M. L. · Breast Cancer Targets Ther. · 2015 · 7 · 231
72. 10.1038/bjc.2014.6110.1038/bjc.2014.61 ↗
73. 10.1023/B:HIJO.0000032357.16261.c510.1023/B:HIJO.0000032357.16261.c5 ↗
74. 10.1016/j.prp.2011.06.00910.1016/j.prp.2011.06.009 ↗
75. 10.1158/0008-5472.CAN-11-366610.1158/0008-5472.CAN-11-3666 ↗
76. Imaizumi A. · Anticancer Res. · 2016 · 36 · 653
77. Kristiansen G. · Clin. Cancer Res. · 2003 · 9 · 4906
78. 10.1016/j.humpath.2007.12.00310.1016/j.humpath.2007.12.003 ↗
79. 10.1038/ncomms1044210.1038/ncomms10442 ↗
80. 10.1016/j.prp.2015.05.01110.1016/j.prp.2015.05.011 ↗
81. 10.1186/1476-4598-13-20710.1186/1476-4598-13-207 ↗
82. 10.3892/ol.2016.414510.3892/ol.2016.4145 ↗
83. 10.18632/oncotarget.883710.18632/oncotarget.8837 ↗
84. 10.1007/s00432-014-1750-z10.1007/s00432-014-1750-z ↗
85. Ieni A. · Anticancer Res. · 2011 · 31 · 1315
86. 10.1016/j.jconrel.2013.07.01410.1016/j.jconrel.2013.07.014 ↗
87. 10.1002/stem.32410.1002/stem.324 ↗
88. 10.1038/ng.12710.1038/ng.127 ↗
89. 10.1038/onc.2011.33810.1038/onc.2011.338 ↗
90. 10.1002/emmm.20130341110.1002/emmm.201303411 ↗
91. 10.1158/0008-5472.CAN-10-332010.1158/0008-5472.CAN-10-3320 ↗
92. 10.1073/pnas.160288311310.1073/pnas.1602883113 ↗
93. 10.1038/nmat251510.1038/nmat2515 ↗
94. Ham S. L. · J. Vis. Exp. · 2015 · e52754
95. 10.1007/978-1-59745-443-8_810.1007/978-1-59745-443-8_8 ↗